![]() Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Hemorrhagic complications of anticoagulant treatment. Levine MN, Raskob G, Landefeld S, Hirsh J. Pharmacokinetics and pharmacodynamics of warfarin at steady state. Routledge PA, Chapman DH, Davies DM, Rawlins MD. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Generic warfarin: implications for patient care. Establishing an outpatient anticoagulation clinic in a community hospital. Therapy of acute thromboembolism with heparin and warfarin. ![]() Oral anticoagulant therapy-50 years later. Monitoring effects of oral anticoagulants during treatment with heparin. Thomas P, Fennerty A, Backhouse G, Bentley DP, Campbell IA, Routledge PA. Aging and the anticoagulant response to warfarin therapy. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffatt K, Hirsh J. In: Evans WE, Schentag JJ, Jusko WJ, eds. Goodman and Gilman’s The pharmacological basis of therapeutics. Anticoagulant thrombolytic, and antiplatelet drugs. Majerus PW, Broze GJ, Miletich JP, Tollefsen DM. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, et al. Antithrombotic therapy in atrial fibrillation. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al. Antithrombotic therapy in valvular heart disease. Antithrombotic therapy in patients with mechanical and biologic prosthetic heart valves. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Retrieved November 1998 from the World Wide Web at. Life-saving treatments to prevent stroke underused. Plymouth Meeting, Pa.: IMS America, 1998.Īgency for Health Care Policy and Research. Retail perspective and provider perspective audit. ![]() Plymouth Meeting, Pa.: IMS America, 1998. National prescription audit: physician specialty report, dispensed data. Valvular heart disease (after thrombotic event or if the left atrium is greater than 5.5 cm)ģ weeks before and 4 weeks after atrial fibrillation if normal sinus rhythm is maintained Thrombosis associated with antiphospholipid antibodyĪcute myocardial infarction (to prevent systemic embolism) † Prophylaxis of venous thrombosis for high-risk surgery ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |